Sign in
TIL Stock Price, Chart, Stats & News
Instil Bio, Inc.
Save
51.81M
Market cap
–
Current P/E
–
Forward P/E
TIL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -35.07% |
ROE | -55.88% |
D/E | 0.75x |
Interest coverage ratio | -13.48x |
TIL valuation
P/E | – |
P/S | – |
P/B | 0.46x |
P/CF | -1.44x |
P/FCF | -1.44x |
P/OCF | -1.44x |
PEG | -0.14x |
EV multiple | 0.38x |
About
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer.
Similar securities
Based on sector and market capitalization
Report issue